# Kite Pharma

Kite Pharma is an Asset Manager based in Santa Monica, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Santa Monica, United States
- **Region:** North America
- **Address:** Santa Monica, CA, United States
- **Assets under management:** Undisclosed
- **Website:** kitepharma.com
- **LinkedIn:** https://www.linkedin.com/company/kite-pharma-inc-

## Regulatory record

- **Reports private funds:** No

## About

Kite is dedicated to curing cancer. Learn about the science of cell therapy, our cancer research, and our cancer treatments in the pipeline.

## Sectors

- Healthcare Services

## Offices

- Menlo Park, CA
- New York, NY
- Bala Cynwyd, PA
- San Francisco, CA

## Questions

### Who runs investment decisions at Kite Pharma?

Kite Pharma does not manage external investment capital; it is a wholly owned clinical-stage and commercial biotherapeutics subsidiary of Gilead Sciences. Strategic and capital-allocation decisions — including the 2017 acquisition and subsequent bolt-on deals like Arcellx — are made by Gilead's executive leadership and board. The Kite unit is not a family office or fund and does not allocate to outside managers.

### What assets does Kite Pharma have under management?

Kite Pharma does not manage third-party assets and does not report an AUM figure. As a consolidated subsidiary of Gilead, its R&D and commercial expenditures are funded through the parent's corporate balance sheet. Gilead's oncology segment, which encompasses Kite, reported $2.2 billion in revenue for full-year 2025 (per Gilead annual filing, 2026).

### Which investment stages does Kite Pharma typically target?

Kite is not a fund investor. It acquires companies — such as the $2.5 billion Arcellx deal announced in February 2026 — and in-licenses technology platforms at late preclinical or early clinical stages to feed its pipeline. The unit does not make venture-stage minority investments as a core activity.

### How is Kite Pharma related to Gilead Sciences?

Kite Pharma has been a wholly owned subsidiary of Gilead Sciences since the acquisition closed in October 2017 for roughly $11.9 billion in cash. Gilead maintains Kite as a distinct brand and operational unit within its oncology segment, and Kite's clinical, regulatory, and manufacturing activities are reported through Gilead's consolidated financials.

## Related profiles

- [Meriplex Communications](https://altss.com/profile/meriplex-communications-ltd)
- [CloudHesive](https://altss.com/profile/cloudhesive)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/kite-pharma

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology